Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump
Executive Summary
Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations
You may also be interested in...
Genentech Bets On Kineta's Early-Stage, Disease-Modifying Pain Therapy
Genentech partners with the Seattle biotech on a non-opioid approach to chronic pain. Kineta says there's disease-modifying potential.
Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial
Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)
Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial
Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)